Cargando…
Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles
Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been invest...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356210/ https://www.ncbi.nlm.nih.gov/pubmed/22619536 http://dx.doi.org/10.2147/IJN.S28245 |
_version_ | 1782233521218125824 |
---|---|
author | Huang, Kai-Wen Yang, Shieh-Yueh Hong, Yu-Wei Chieh, Jen-Jie Yang, Che-Chuan Horng, Herng-Er Wu, Chau-Chung Hong, Chin-Yih Yang, Hong-Chang |
author_facet | Huang, Kai-Wen Yang, Shieh-Yueh Hong, Yu-Wei Chieh, Jen-Jie Yang, Che-Chuan Horng, Herng-Er Wu, Chau-Chung Hong, Chin-Yih Yang, Hong-Chang |
author_sort | Huang, Kai-Wen |
collection | PubMed |
description | Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was used as a target biomolecule. The signals for AFP solutions of various concentrations, or with interfering materials, were detected via IMR. These samples were also used for characterizing the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The results of assaying AFP level with IMR and ELISA were compared. The detection threshold for assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, and definitely suppresses false negative. For the interfering materials noted commonly in serum such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no detectable interfering effect when assaying AFP with IMR. Several serum samples from normal people and liver-tumor-bearing patients were used for the detections of AFP concentration via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as achieving high-sensitive and high-specific assay for AFP. |
format | Online Article Text |
id | pubmed-3356210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-33562102012-05-22 Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles Huang, Kai-Wen Yang, Shieh-Yueh Hong, Yu-Wei Chieh, Jen-Jie Yang, Che-Chuan Horng, Herng-Er Wu, Chau-Chung Hong, Chin-Yih Yang, Hong-Chang Int J Nanomedicine Original Research Some previous reports have already shown the characterizations of immunomagnetic reduction (IMR). The assay technology involves the utilities of biofunctionalized magnetic nanoparticles to label target biomolecules. However, the detection threshold and interference tests for IMR have not been investigated in detail. In this study, alpha-fetoprotein (AFP) was used as a target biomolecule. The signals for AFP solutions of various concentrations, or with interfering materials, were detected via IMR. These samples were also used for characterizing the detection threshold and interference with enzyme-linked immunosorbent assay (ELISA). The results of assaying AFP level with IMR and ELISA were compared. The detection threshold for assaying AFP with IMR was found to be 3 ng/mL, which is 15 times lower than that of ELISA, and definitely suppresses false negative. For the interfering materials noted commonly in serum such as hemoglobin, bilirubin, triglyceride, and vascular endothelial growth factor, there was no detectable interfering effect when assaying AFP with IMR. Several serum samples from normal people and liver-tumor-bearing patients were used for the detections of AFP concentration via IMR. These results reveal the feasibilities of assaying AFP in blood using IMR, as well as achieving high-sensitive and high-specific assay for AFP. Dove Medical Press 2012 2012-04-17 /pmc/articles/PMC3356210/ /pubmed/22619536 http://dx.doi.org/10.2147/IJN.S28245 Text en © 2012 Huang et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Huang, Kai-Wen Yang, Shieh-Yueh Hong, Yu-Wei Chieh, Jen-Jie Yang, Che-Chuan Horng, Herng-Er Wu, Chau-Chung Hong, Chin-Yih Yang, Hong-Chang Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title | Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title_full | Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title_fullStr | Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title_full_unstemmed | Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title_short | Feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
title_sort | feasibility studies for assaying alpha-fetoprotein using antibody-activated magnetic nanoparticles |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356210/ https://www.ncbi.nlm.nih.gov/pubmed/22619536 http://dx.doi.org/10.2147/IJN.S28245 |
work_keys_str_mv | AT huangkaiwen feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT yangshiehyueh feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT hongyuwei feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT chiehjenjie feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT yangchechuan feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT hornghernger feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT wuchauchung feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT hongchinyih feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles AT yanghongchang feasibilitystudiesforassayingalphafetoproteinusingantibodyactivatedmagneticnanoparticles |